Holen Sie sich die Stockscreener-App
24.77
0.32%
0.08
Handel nachbörslich:
24.69
-0.08
-0.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Affiliate sales notice for RARE (NASDAQ: RARE) lists recent Howard Horn transactions - Stock Titan
Pictet Asset Management Holding SA Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
MSN Money - MSN
Ultragenyx falls as guidance trails consensus amid job cuts - MSN
symbol__ Stock Quote Price and Forecast - CNN
Rare's DTX301 meets first key goal in Phase III OTC deficiency study - MSN
Vanguard Portfolio Management discloses 5.5% stake in Ultragenyx (RARE) - Stock Titan
Ultragenyx earnings: What to watch as pipeline faces key test By Investing.com - Investing.com India
Ultragenyx earnings: What to watch as pipeline faces key test - Investing.com
Barclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat
RARE Maintained by Barclays -- Price Target Lowered to $43 - GuruFocus
Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial - Yahoo Finance UK
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update - GlobeNewswire
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rare rises as FDA accepts resubmitted BLA for Sanfilippo syndrome - MSN
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
FDA decision on UX111 gene therapy for Sanfilippo expected in September - Sanfilippo Syndrome News
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA - MSN
RARE stock slumps on multiple Wall Street price target slashes, clinical pipeline uncertainty - MSN
Teacher Retirement System of Texas Purchases 327,502 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Above 50-Day Moving AverageHere's Why - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ultragenyx (RARE) SVP Huizenga awarded RSUs and option grant - Stock Titan
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(RARE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Is Ultragenyx Pharmaceutical (RARE) Now Attractive After Recent 8.1% Weekly Share Price Jump - Sahm
Ultragenyx (RARE) CEO gets new RSUs, options and shifts 400K shares - Stock Titan
Ultragenyx (RARE) awards RSUs and 79,936 stock options to officer - Stock Titan
Ultragenyx (RARE) awards RSUs and stock options to executive Pinion - Stock Titan
Ultragenyx (RARE) grants EVP 28,895 RSUs and 49,960 options - Stock Titan
Ultragenyx (RARE) EVP Harris receives RSU and option grants in equity award - Stock Titan
Ultragenyx (RARE) CMO receives 34,674 RSUs and 59,952 stock options - Stock Titan
Ultragenyx (RARE) CFO granted 34,674 RSUs and 59,952 options in equity awards - Stock Titan
Ultragenyx Pharmaceutical stock (US74930A1043): Does its rare disease focus deliver the growth U.S. - AD HOC NEWS
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Osteogenesis Imperfecta Market to Expand Significantly by 2034 with Advancements in Novel Therapies and Rising Disease Awareness, Reports DelveInsight - Barchart.com
Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight - Barchart.com
Massachusetts Financial Services Co. MA Has $7.13 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Free cash flow per share of Ultragenyx Pharmaceutical, Inc. – BIVA:RARE - TradingView — Track All Markets
RARE Maintained by Morgan Stanley -- Price Target Raised to $67 - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Bear Alert: What are the future prospects of Ultragenyx Pharmaceutical IncWeekly Earnings Recap & Safe Capital Growth Tips - baoquankhu1.vn
Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts (NASDAQ:RARE) - Seeking Alpha
Ultragenyx Pharmaceutical Inc. $RARE Stock Position Cut by SG Americas Securities LLC - MarketBeat
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):